SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

Sage Therapeutics Q1 EPS $(2.440) Beats $(3.140) Estimate, Sales $2.300M Miss $2.800M Estimate

Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(2.440) per share which beat the analyst consensus estimate of $(3.140) by 22.29 percent. This is a 27.6 percent increase over losses of $(3.370) per share

Benzinga · 05/07/2020 20:11

Sage Therapeutics (NASDAQ:SAGE) reported quarterly losses of $(2.440) per share which beat the analyst consensus estimate of $(3.140) by 22.29 percent. This is a 27.6 percent increase over losses of $(3.370) per share from the same period last year. The company reported quarterly sales of $2.300 million which missed the analyst consensus estimate of $2.800 million by 17.86 percent. This is a 394.62 percent increase over sales of $465.000 thousand the same period last year.